Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market By Disease Type (Benign Focal Amyotrophy of ALS, Infantile Spinal Muscular Atrophy, Juvenile Spinal Muscular Atrophy, Kugelberg-Welander Disease, Primary Lateral Sclerosis, Progressive Bulbar Palsy, Spinal Muscular Atrophy, Upper Motor Neuron Disease, Werdnig-Hoffman Disease and Wohlfart-Disease), Drug Type (Riluzole, Edaravone (Radicava) and Others), Distribution Channel (Hospital Pharmacies, and Retail and Online Pharmacies), Treatment type (Chemotherapy and Stem Cell Therapy) End User (Hospitals, Homecare, Specialty Clinics and Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Data Bridge Market Research analyses that the amyotrophic lateral sclerosis (ALS) treatment market will exhibit a CAGR of around 6.10% for the forecast period of 2021-2028. Increasing awareness and concerns regarding the health of patients, increasing public and private expenditure for the development of healthcare infrastructure especially in emerging economies and increased expenditure on research and development activities by the pharmaceutical companies to develop novel therapeutics are the major factors attributable to the growth of amyotrophic lateral sclerosis (ALS) treatment market.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease, also known as Lou Gehrig's disease and motor neuron disease (MND). It is a disease that has an adverse effect over nerve cells in brain and spinal cord that are responsible for controlling the voluntary muscles.
Upsurge in the prevalence of amyotrophic lateral sclerosis (ALS) globally is one of the major factors inducing growth in the demand for amyotrophic lateral sclerosis (ALS) treatment. Rising expenditure for research and development proficiencies by the pharmaceutical and biotechnological industries will further generate lucrative and remunerative growth opportunities for the market. Rising adoption of advanced healthcare technological solutions will also act as important market growth determinants. Rising geriatric population susceptible to amyotrophic lateral sclerosis (ALS) will also propel growth in the market value.
However, high costs associated with amyotrophic lateral sclerosis (ALS) treatment will derail the market growth rate. Fewer initiatives taken by the government to spread awareness will also create obstructions for the amyotrophic lateral sclerosis (ALS) treatment market.
This amyotrophic lateral sclerosis (ALS) treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on amyotrophic lateral sclerosis (ALS) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Scope and Market Size
The amyotrophic lateral sclerosis (ALS) treatment market is segmented on the basis of disease type, drug type, distribution channel, treatment type and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- By disease type, the global amyotrophic lateral sclerosis (ALS) treatment market is segmented into benign focal amyotrophy of ALS, infantile spinal muscular atrophy, juvenile spinal muscular atrophy, kugelberg-welander disease, primary lateral sclerosis, progressive bulbar palsy, spinal muscular atrophy, upper motor neuron disease, werdnig-hoffman disease and wohlfart-disease.
- On the basis of drug type, the global amyotrophic lateral sclerosis (ALS) treatment market is segmented into riluzole, edaravone (radicava) and others.
- On the basis of distribution channel, the amyotrophic lateral sclerosis (ALS) treatment market is segmented into hospital pharmacies, retail and online pharmacies.
- On the basis of treatment type, the amyotrophic lateral sclerosis (ALS) treatment market is segmented into chemotherapy and stem cell therapy.
- On the basis of end user, the amyotrophic lateral sclerosis (ALS) treatment market is segmented into hospitals, home care, speciality clinics and others.
Amyotrophic Lateral Sclerosis (ALS) Treatment Market Country Level Analysis
The amyotrophic lateral sclerosis (ALS) treatment market is analysed and market size insights and trends are provided by country, disease type, drug type, distribution channel, treatment type and end user as referenced above.
The countries covered in the amyotrophic lateral sclerosis (ALS) treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the amyotrophic lateral sclerosis (ALS) treatment market owing to the existence of advanced healthcare solutions coupled with favourable reimbursement scenario in the region. Asia-Pacific on the other hand is projected to undergo the highest growth rate during the forecast period owing to the increasing revenue generation from riluzole generic manufacturers and improving healthcare infrastructure.
The country section of the amyotrophic lateral sclerosis (ALS) treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
Amyotrophic lateral sclerosis (ALS) treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for digital health technologies market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the amyotrophic lateral sclerosis (ALS) treatment market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Analysis
The amyotrophic lateral sclerosis (ALS) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to amyotrophic lateral sclerosis (ALS) treatment market.
The major players covered in the amyotrophic lateral sclerosis (ALS) treatment market report are F. Hoffmann-La Roche Ltd, Mitsubishi Tanabe Pharma Corporation., Sanofi, Otsuka Holdings Co., Ltd., Biogen, BrainStorm Cell Limited., CORESTEM, Inc., Biohaven Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Ionis Pharmaceuticals, AB Science, Genervon Biopharmaceuticals, LLC., Orphazyme A/S, Bausch Health Companies Inc., Orion Corporation., KRIGLE PHARMA, INC, Aquestive Therapeutics, Inc., Apotex Inc., Seneca Biopharmaceuticals, Inc. and TREEWAY among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Customization Available : Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.